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Abstract
Background: Celecoxib (Celebrex), a widely prescribed selective inhibitor of cyclooxygenase-2, can modulate ion channels
independently of cyclooxygenase inhibition. Clinically relevant concentrations of celecoxib can affect ionic currents and
alter functioning of neurons and myocytes. In particular, inhibition of Kv2.1 channels by celecoxib leads to arrhythmic
beating of Drosophila heart and of rat heart cells in culture. However, the spectrum of ion channels involved in human
cardiac excitability differs from that in animal models, including mammalian models, making it difficult to evaluate the
relevance of these observations to humans. Our aim was to examine the effects of celecoxib on hERG and other human
channels critically involved in regulating human cardiac rhythm, and to explore the mechanisms of any observed effect on
the hERG channels.
Methods and Results: Celecoxib inhibited the hERG, SCN5A, KCNQ1 and KCNQ1/MinK channels expressed in HEK-293 cells
with IC50s of 6.0 mM, 7.5 mM, 3.5 mM and 3.7 mM respectively, and the KCND3/KChiP2 channels expressed in CHO cells with
an IC50 of 10.6 mM. Analysis of celecoxib’s effects on hERG channels suggested gating modification as the mechanism of
drug action.
Conclusions: The above channels play a significant role in drug-induced long QT syndrome (LQTS) and short QT syndrome
(SQTS). Regulatory guidelines require that all new drugs under development be tested for effects on the hERG channel prior
to first administration in humans. Our observations raise the question of celecoxib’s potential to induce cardiac arrhythmias
or other channel related adverse effects, and make a case for examining such possibilities.
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Introduction
Coxibs, selective inhibitors of cyclooxygenase-2 (COX-2), were
developed to replace ‘‘traditional’’ non-steroidal anti-inflammato-
ry drugs (NSAIDs) in the treatment of arthritis and acute pain.
Four coxibs were marketed as NSAIDs with reduced gastrointes-
tinal side effects. However, with high prevalence of serious
cardiovascular complications among patients using Vioxx (rofe-
coxib), it was withdrawn in 2004, followed by removal of Bextra
(valdecoxib) in 2005.
Celecoxib (Celebrex), one of the two coxibs remaining on the
market (etoricoxib, or Arcoxia, is prescribed worldwide but not in
the USA), also may cause an increased risk of serious and
potentially fatal adverse cardiovascular thrombotic events, myo-
cardial infarction, and stroke. The hazard ratio for the composite
endpoint of cardiovascular complications is 3.4 for 400 mg
celecoxib twice daily and 2.8 for 200 mg celecoxib twice daily
compared to placebo [1].
Celecoxib targets cellular and enzymatic mechanisms other
than cyclooxygenases, including voltage-activated Na
+,K
+ and
Ca
2+ channels [2–5]. We have shown that celecoxib can directly
inhibit K
+ channels in fruit flies, and K
+ and Na
+ channels in
mammals, with strong effects on cardiomyocyte and neuronal
function [6,7]. We have also shown that celecoxib and SC-791 (a
highly selective COX-2 inhibitor) can inhibit Kv2.1 channels
expressed in HEK-293 cells via modification of gating and channel
block [8,9]. In addition, it has been reported that celecoxib and its
inactive analog, 2,5-dimethyl-celecoxib (DMC), but not rofecoxib,
can acutely and reversibly up-regulate currents through Kv7.5
(KCNQ5) cardiac channels, while inhibiting other currents [4].
Celecoxib can similarly inhibit Kv1.5, Kv7.1 and Kv4.3 channels
and alter action potential duration in mouse and guinea pig
cardiomyocytes [10].
There are significant differences between the ionic basis of
cardiac excitability in humans and that in animal models. In
humans, drug effects on hERG, SCN5A (Nav1.5), KCNQ1/MinK
and KCND3/KChiP2 (Kv4.3) channels often lead to Long QT
syndrome (LQTS) or Short QT syndrome (SQTS), including
Torsade de Pointes (TdP) arrhythmias, fraught with ventricular
fibrillation and ultimately death [11,12]. In particular, hERG
channel, the molecular basis of the rapidly activating K
+ current
(IKr), is implicated in many life-threatening cardiac arrhythmias
[13–18], and guidelines (ICH S7B) from regulatory agencies in the
USA, European Union and Japan require that any new drug
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26344under development be tested for effects on the hERG current prior
to first administration in humans [19].
The above observations on the widely prescribed celecoxib raise
a question on its possible effects on hERG and other human
channels. The main focus of this study was to examine the effect of
celecoxib on hERG channels expressed in HEK-293 cells and the
mechanism underlying this effect. In addition, we explored if
celecoxib inhibited human SCN5A channels, examined concen-
tration dependence of inhibition of human KCNQ1, KCNQ1/
MinK and KCND3/KChiP2 channels [10], and studied the
nature of inhibition of human KCNQ1/MinK channels.
Results
Inhibition of hERG channels
The hERG channel is the most critical channel involved in
genetic or drug-induced Torsade de Pointes (TdP) arrhythmias.
Extracellular application of celecoxib caused rapid suppression of
hERG1a channels (Figures 1, 2). Celecoxib inhibited depolariza-
tion-induced current and the tail current to a similar extent
(Figure 1A) suggesting a voltage-independent mechanism. 10 mM
celecoxib inhibited the tail currents by 64% at 240 mV and 47%
at 2130 mV. IC50 was 6.0 mM( Figure 1B). The inhibition was
reversible, with the time constant of 12.060.7 s for its onset (ton)
and 9.861.8 s for recovery from inhibition (off)a t1 0 mM
celecoxib.
Examining effects of the drug on hERG during prolonged
depolarizations can help distinguish between closed-channel block
and a slow open-channel block. During the first instance of
channel activation after application of an open-channel blocker,
the blockade begins with relatively little inhibition. As more
channels become blocked, the current decreases faster than in
control. Because open-channel blockers usually dissociate from the
channels held at hyperpolarizing potentials, such blockade is only
partially relieved during inter-pulse intervals, thus resulting in
consecutive current traces of gradually decreasing amplitude [20–
22]. On the other hand, blockade of ion channels in their closed
state(s) is often characterized by time- and voltage-dependent relief
of inhibition during depolarization [23].
Experimental protocol consisted of eight identical voltage pulses
(Figure 2A). The first four 10-s pulses from a holding potential (HP)
of 280 mV to 0 mV applied in control to ensure stability of
recordings were followed by a rapid wash-in of 10 mM celecoxib. Stimulation was resumed after 3 min exposure to celecoxib with
the cell held at 280 mV. No difference was observed between
currents for pulses 5 and 6 in the presence of the drug (green and
red traces superimpose in Figure 2A-‘celecoxib’). This indicated that
celecoxib either did not dissociate from hERG during inter-pulse
interval (thus suggesting the unlikelihood of a slow open-channel
block), or that open-channel block developed very fast. In
addition, as there was no relief of inhibition during depolarizing
pulse, the drug did not appear to block closed channels.
To examine the possibility of a rapid open-channel block, 1 Hz
train of short depolarizations was used to elicit hERG tail currents
at 2130 mV (with 100 ms pre-pulse to +60 mV). After 20 pulses
under control conditions, 10 mM celecoxib was added and allowed
to equilibrate for 3 min with the cell held at 280 mV. By
comparing the first tail current obtained in the presence of the
drug with consecutive recordings and with current traces in
control, it may be possible to detect a fast open-state block.
Amplitude of the first tail in the presence of celecoxib was 55% of
the last tail in control and did not decrease further with continued
stimulation (Figure 2B). Similar observations were made with a
40 ms pre-pulse to +60 mV as well (data not shown). As the time
constant for inactivation at +60 mV was 1.460.2 ms, only very
Figure 1. Effects of celecoxib on hERG. (A) The hERG current in
control (blue), after application of 10 mM celecoxib (green) and after
wash-out (red). The currents were elicited by a 10 s pulse to 260 mV
following a 10 s pre-pulse to 0 mV (HP=280 mV). (B) Dose-response
relations for the peak tail currents evoked by a pulse to 240 mV after a
2 s pre-pulse to +40 mV; here and in the following figures the dose-
response relations have been fitted to the Hill equation; number of cells
varied between 3 and 11.
doi:10.1371/journal.pone.0026344.g001
Figure 2. Onset of hERG inhibition. (A) Four 10 s pulses to 0 mV in
control with 30 s inter-pulse intervals were followed by four pulses after
3 min exposure to 10 mM celecoxib. Data from 9 experiments were
divided by maximum value of current in control in each cell and then
averaged. Traces labeled ‘celecoxib’ overlap for pulses 5 (green) and 6
(red). (B) Celecoxib modulates closed hERG channels. Currents were
elicited by 1 Hz pulse trains consisting of a 100 ms pre-pulse to +60 mV
followed by a 150 ms pulse to 2130 mV. After 20 pulses in control, the
stimulation was ceased and 10 mM celecoxib was rapidly washed in
(arrow). Stimulation was resumed after 3 min exposure to the drug
while holding the cell at 280 mV; number of experiments, 4; inset
shows an example of tail currents. (C) Inhibition of hERG was not use-
dependent. Currents were evoked by 1 Hz pulse train consisting of a
400 ms pre-pulse to +20 mV followed by a 200 ms pulse to 240 mV
and normalized to the magnitude of current during the first pulse in
each sample; (n), number of experiments in this and the following
figures. (D) Duration of the inter-pulse interval did not affect the extent
of inhibition. Currents were elicited as in the panel C.A f t e r
development of inhibition at 0.2 Hz in the presence of 10 mM celecoxib,
the frequency of stimulation was first switched to 0.1 Hz for 10 pulses,
and then to 1 Hz for 60 pulses; average of 3 cells.
doi:10.1371/journal.pone.0026344.g002
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reach steady state level of inhibition during brief depolarizing pre-
pulse without causing progressive reduction in tail currents. This
experiment, however, cannot rule out a rapid inactivated-channel
blockade (binding of a blocker to the pore of inactivated channel),
which could have been established during the first occurrence of
depolarization (100 or 40 ms pre-pulse to +60 mV). To further
explore this possibility, use-dependence of hERG inhibition was
tested at 1 Hz. No use-dependence of inhibition was found
(Figure 2C).
A closed-channel blockade is characterized by use-dependent
unblock [23]. This possibility was examined by stimulating the
cells at different frequencies to see if inhibition was partially
relieved at higher pulsing rates (Figure 2D). This protocol did not
increase the tail current amplitude at 1 Hz, indicating the
unlikelihood of closed-channel block.
Modification of hERG1a gating
Closer examination of the initial 200 ms of recordings in
Figure 2A revealed a ‘‘cross-over’’ of the current in control with that
during the first few pulses in the presence of celecoxib (Figure 3A):
the current in the presence of celecoxib transiently rose above that
in control and peaked around 15 ms after the beginning of the
voltage pulse (P,0.05, t-test).
Because transient increase in current on drug application is
consistent with modification of channel gating but not with
channel block, we explored celecoxib’s effects on hERG kinetics.
Figure 3C,D shows the effects of celecoxib on voltage-dependent
properties of hERG after prolonged exposure. The current
showed a threshold for activation at 250 mV, with inward
rectification typical of hERG. Sustained current (current at the
end of a 4 s pre-pulse) reached a maximum at +10 mV in control
and at 220 mV in the presence of the drug. Importantly, current-
voltage relations for the sustained currents demonstrated cross-
over at 240 mV where the current in the presence of celecoxib
was significantly larger than that in control (P,0.01, t-test,
Figure 3C). Similarly to the transient increase in current during first
instances of stimulation after drug application, there was a
transient hERG increase even after prolonged drug exposure
and repeated stimulation (at 220 mV, P,0.01, t-test, Figure 3C).
Deactivating tail currents, determined at 260 mV, displayed
sigmoid voltage dependence and saturated at +10 mV. Celecoxib
caused a hyperpolarizing shift in the half-activation potential
(V
a
K) (determined using Boltzmann equation): from 216.26
1.2 mV in control to 227.661.5 mV at 10 mM celecoxib
(Figure 3D). In addition, augmentation of the sustained currents
in the presence of celecoxib resulted in the cross-over of I-V curves
for the tail currents with significantly larger current (P,0.03) in
the presence of celecoxib at 240 mV (Figure 3D).
Activation time constants (tact) were determined between 0 and
+40 mV using the envelope of tail currents method (Figure 4A).
The data points were fitted with a single exponential function to
obtain tact. Celecoxib significantly decreased tact between 0 and
+20 mV (Figure 4B).
To obtain the inactivation time constants (tinact), the time course
of decay of large transient outward inactivating hERG current was
fitted with a single exponential function. Celecoxib significantly
reduced tinact between 220 and +30 mV (Figure 4C,D). Recovery
of hERG from inactivation proceeds from inactivated to open state
followed by deactivation. The time constants for re-activation
(treact) were determined by fitting the time course of re-activating
currents (Figure 4E) with a single exponential function. The voltage
dependence of recovery was bell-shaped and celecoxib decreased
the values of treact between 260 and 220 mV (Figure 4F).
Celecoxib did not affect deactivation kinetics of the hERG
channels (data not shown).
Inhibition of KCNQ1 and KCNQ1/MinK by celecoxib
While hERG channels are responsible for the largest proportion
of drug-induced TdP arrhythmias, KCNQ1/MinK channels pass
the slow cardiac delayed rectifier current IKs [24,25] and also play
a significant role in such arrhythmias. Loss of function mutations
or pharmacological inhibition of KCNQ1 can result in LQTS
forms 1 and 5 [24,26]. Gain of function mutations in KCNQ1 can
cause SQTS and atrial fibrillation [27,28].
Celecoxib inhibited KCNQ1/MinK and KCNQ1 currents in
concentration-dependent manner (Figure 5). The IC50 values were
3.7 mM for KCNQ1/MinK and 3.5 mM for KCNQ1 (Figure 5E).
Effects of celecoxib were reversible, with the ton of 42.361.4 s
and the toff of 112.769.7 s for KCNQ1/MinK and ton of
37.162.4 s and toff of 114.1614.8 s for KCNQ1. To determine if
celecoxib exerted its effects on the closed channels, we examined
the time course of the current after exposure of cells held at
280 mV, without electric stimulation, to 3 mM celecoxib. The
protocol consisted of 0.1 Hz train of ten 1 s pulses to +40 mV
under control conditions, a rapid application of 3 mM celecoxib
with the cells held at 280 mV without stimulation, and
resumption of stimulation after 5 min long exposure (Figure 5F).
The amplitudes of the first pulses in the presence of the drug, after
this stimulus-free exposure, were 69% and 64% of the controls for
KCNQ1/MinK and KCNQ1, respectively and did not decrease
with further stimulation, suggesting drug effect on closed channels.
Figure 3. Modification of hERG gating by celecoxib. (A)
Expanded first 200 ms from Fig. 2A shows a transient increase in hERG
amplitude in the presence of celecoxib at 15 ms (vertical line) after the
onset of pulse; gray traces indicate the range of SE. (B) Examples of
hERG in control elicited by 4 s pulses to 260 mV after 4 s pre-pulses to
voltages between 260 and +40 mV in 10 mV increments. (C)
Normalized voltage-current relations for the sustained (end of a 4 s
pre-pulse) and transient (maximal amplitude during the first 20 ms of
pulse) components of hERG in control and at 10 mM celecoxib; currency
signs mark statistical significance for circles, asterisks – for triangles. (D)
Voltage-dependence of peak tail currents plotted against the pre-pulse
voltage in control and at 10 mM celecoxib.
doi:10.1371/journal.pone.0026344.g003
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these channels, nor did it alter the values of V
a
K.
Inhibition of SCN5A
SCN5A channel is the major source of depolarization during
action potential in human myocardium. Mutations in SCN5A can
cause various cardiac disorders including LQTS and Brugada
syndrome and the channel is the molecular target of antiarrhyth-
mics, local anesthetics, and various off-mark medicines that may
cause drug-induced LQTS [29,30].
Although celecoxib was shown to inhibit sodium currents in rat
dorsal root ganglion and retinal neurons [3,7], the molecular bases
of those currents are not known. In the present study we examined
if celecoxib could inhibit human SCN5A. Celecoxib inhibited
SCN5A currents evoked from the holding potentials (HP) of 270
and 2100 mV with respective IC50s of 7.5 and 15.7 mM
(Figure 6A,B,D).
Inhibition of KCND3
The KCND3 channel constitutes an important component of
cardiac transient outward potassium current Ito in human heart.
Expression of KCND3 is altered in inherited and acquired cardiac
pathologies such as Brugada syndrome or congestive heart failure
[31,32].
We examined effects of celecoxib on KCND3 channels stably
expressed in the CHO cell line. Celecoxib inhibited the peak
KCND3 current with an IC50 of 10.6 mM( Figure 6C,D).
Discussion
Celecoxib has been shown to inhibit ion channels and induce
arrhythmic beating in rat heart cells in cultures and Drosophila
heart [6]. Here we show its inhibition of human ether-a-go-go
related gene (hERG) channels, which are the most common
substrate of drug-induced TdP arrhythmias in humans, and study
the mechanism underlying this inhibition. In addition, the drug
inhibited other human channels - SCN5A, KCNQ1/MinK and
KCND3 - involved in TdP arrhythmias, in a concentration
dependent manner.
Figure 5. Effects of celecoxib on the KCNQ1/MinK and KCNQ1
channels. KCNQ1/MinK (A, B) and KCNQ1 (C, D) currents were elicited
by voltage pulses between 280 mV and +40 mV in 10 mV increments
(HP=280 mV). (E) Dose-response relations for the KCNQ1/MinK current
at the end of 2 s pulse and for the peak KCNQ1 current (at +40 mV);
number of experiments varied between 3 and 18. (F) Celecoxib
modulated closed channels; currents were elicited by 0.1 Hz train
consisting of 1 s pulses to +40 mV. After 10 pulses in control, the
stimulation was paused and 3 mM celecoxib rapidly washed in (arrow).
Stimulation was resumed after 5 min exposure to celecoxib.
doi:10.1371/journal.pone.0026344.g005
Figure 4. Celecoxib accelerated kinetics of activation, inacti-
vation and re-activation of the hERG channels. (A) Examples of
currents recorded during envelope-of-tails protocol to measure rates of
activation at +20 mV in control and at 10 mM celecoxib. The protocol
consisted of a variable duration (between 10 and 3,000 ms) pre-pulse to
+20 mV followed by a test pulse to 260 mV. (B) Voltage dependence of
the tact.( C) Examples of inactivating currents in control and at 10 mM
celecoxib. The protocol consisted of a 2 s first pre-pulse to +60 mV, a
10 ms second pre-pulse to 2100 mV, and a test pulse between 220
and +60 mV in 10 mV increments. (D) Voltage dependence of the tinact.
(E) An example of re-activating current in control evoked by a 2 s pre-
pulse to +40 mV followed by a 50 ms test pulse between 2130 and
+10 mV in 10 mV increments. (F) Voltage dependence of the treact.
doi:10.1371/journal.pone.0026344.g004
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tion of gating properties, rather than channel block. There was no
indication of closed channel block. The current did not recover
during prolonged depolarization (Figure 2A), inhibition was not
affected by stimulation frequency (Figure 2D), and channel
activation did not decelerate (Figure 4). Similarly, our data did
not support open- or inactivated-channel block. Effects on
amplitude and kinetics were completely set after 3 min exposure
without stimulation. A rapid or a slow open-channel block was not
likely as there was neither a progressive current decline upon
repeated depolarization after exposure of closed channels to
celecoxib, nor use-dependent decline (Figure 2). Ultra-fast open
channel block with t#1.4 ms (the value of tinact at +60 mV) was
unlikely because of the relatively slow onset of inhibition (ton of
12.060.7 s). Acceleration of recovery from inactivation (Figure 4)
was inconsistent with inactivated-channel block, because the latter
is associated with slowing of recovery due to need for the blocking
molecule to dissociate from the channel pore before the channel
can open again.
On the other hand, the data supported gating modification as
the mechanism of effect on hERG and KCNQ1. The drug altered
voltage-dependence of transitions between different states of the
hERG channel with a facilitating effect as evidenced by changes in
kinetics. It shifted V
a
1/2 towards less positive voltages by 11.4 mV,
aiding activation and causing a transient increase in the current
amplitude and cross-over of I–V curves in a way incompatible
with channel block (Figure 3). It remained bound to closed, open,
and inactivated hERG channels as evidenced by acceleration of
the kinetics of activation, inactivation, and re-activation, respec-
tively. Celecoxib’s effects on KCNQ1 and KCNQ1/MinK were
also compatible with gating modification. Although celecoxib did
not affect channel kinetics except those of inactivation (Figure 5), its
binding to closed channels was not consistent with open channel
block.
Gating modification can accommodate a peculiar characteristic
of changes in kinetics. As drug binding alters the gating rates by a
fixed value of binding energy, the largest effects are expected at
voltages that produce the smallest electrical driving force for the
respective voltage-driven gating transitions, i.e. when the drug
binding energy provides the largest relative contribution to the
gating process. Indeed, celecoxib significantly decreased the tact of
hERG below +30 mV, tinact below +40 mV, and trec between
260 and 220 mV where the electrical driving forces for the
respective transitions were relatively small.
Although celecoxib affects many channels, alters action
potential duration in mouse and guinea pig cardiomyocytes [10],
and induces arrhythmic beating in Drosophila heart and rat heart
cells in culture, known differences between human and animal
cardiac excitability [33] make it difficult to assess the human
relevance of such findings. The human channels examined here,
particularly hERG, are among the most prominent channels
involved in drug-induced fatal TdP in humans.
Current regulations require any Investigational New Drug to be
tested for effects on hERG before its administration in humans. At
the same time, because some hERG inhibitors do not induce TdP
and because a relatively small number of cardiovascular
complications and fatalities due to celecoxib have been reported,
it would be premature to conclude significant clinical implications
from our data. On the other hand, the data do make a case for
further exploring the possibility of such implications, as there are
several factors that may influence clinical outcome of the usage of
celecoxib, and while celecoxib may not induce arrhythmias in
most patients, a small fraction of patients may be susceptible to
arrhythmogenesis.
Adverse effects mediated through ion channels often occur at
low, statistically inconspicuous, level in either pre-clinical trials or
post-marketing usage. However, when a drug is widely used, such
low-incidence effects may assume importance to public health.
There are many cases of post-marketing withdrawal of drugs
where cardiac arrhythmias arising from drug-induced channel
dysfunction led to many deaths over the years before the
seriousness of such effects was realized. For example, at one case
per 100,000 patient-years of exposure, terfenadine (approved in
1985) led to 400 cases of serious injury or death due to cardiac
arrhythmias before its withdrawal in 1998 [34]. Between 1990 and
2001, eight drugs were withdrawn due to cardiac arrhythmias
arising from their use [35]. Many others have since been
withdrawn, including Darvon (approved 1957; withdrawn 2010)
[36].
Celecoxib inhibited the above channels at therapeutic plasma
concentrations, which reach 2.8 mM (6.2 mM in women over 65)
after a single dose of 200 mg and is often higher under many
conditions such as moderate hepatic impairment or co-adminis-
tration of drugs such as ketaconazole [37]. The drug is often used
at dosages of 26200 mg/day or 26400 mg/day. Interpretations
based on these values are complicated by two opposing factors. On
one hand, 97% of the drug is bound to plasma proteins, leaving
only 3% in free form [37]. On the other hand, the volume of
distribution in humans is 4556166 Liters, making the total
amount of drug present in the body close to 100 times that
measured in plasma [37]. This indicates uneven tissue distribution
with much higher concentration, and possibly stronger clinical
implications, in some tissues than in others.
Moreover, significant physiological effects often occur at
concentrations lower than IC50s for channel inhibition. For
example, celecoxib inhibits Na
+ channels in rat retinal neurons
Figure 6. Effects of celecoxib on SCN5A and KCND3. (A–B)
SCN5A currents were evoked by pulses to 220 mV from a HP of
270 mV (A)o r2100 mV (B) in control and in the presence of different
concentrations of celecoxib. (C) Inhibition of KCND3 channels. The
currents were evoked by pulses to +20 mV from a HP of 280 mV. (D)
Dose-response relations for inhibition of peak SCN5A and KCND3
currents; letters in the legend refer to the corresponding panels. A–C,
legends are coded as in the panel A.
doi:10.1371/journal.pone.0026344.g006
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these channels with IC50 of 0.76 mM [7]. This may occur because
a partial inhibition of the Na
+ current may prevent the membrane
potential from reaching the threshold for firing. This would be
similar to the significant risk of TdP known to develop from
relatively small effects on hERG channels arising from genetic or
pharmacological perturbations.
In addition to heart, the above channels express in many other
tissues. For example, the hERG channels play an important role in
smooth muscle contractility, pancreatic beta cell secretion, and
neuronal excitability [38], and are involved in not only TdP but
also other conditions including hyperinsulinemia, inefficient
cortical processing, cognitive deficits and schizophrenia [38,39].
It is premature to ascribe risk of cardiac arrhythmias or other
adverse effects to celecoxib, but with more than one million
prescriptions of Celebrex every month, the data make a case for
exploring the implications of its inhibition of hERG and other
human channels critical to cardiac rhythm and other physiological
functions. Even when a drug is not withdrawn, being alert to its
effects may save lives by taking precautions in specific patients who
might be particularly vulnerable to arrhythmogenic, or other ion
channel related, effects due to genetic or other factors.
On a general note, previous studies have established that ion
channel inhibition is not a generic feature of coxibs, but rather that
of celecoxib and some other structurally similar compounds not
used in therapeutics [2,4,9]. Out of the four prescribed coxibs,
effects on ion channels of only two of them, celecoxib and
rofecoxib, have been investigated. Rofecoxib does not alter ion
channel function [2,4]. Of the remaining two, valdecoxib was
removed from the market in 2005 and thus its possible action on
ion channels is of no acute clinical importance. However, effects of
etoricoxib on ion channels remain unknown and remain a possibly
important issue to explore.
Materials and Methods
Celecoxib was purified from commercial capsules as previously
described, and was of .98% purity as determined by LC mass
spectrometry and NMR spectroscopy
8.
Cell Culture
HEK-293 cells stably transfected with cDNA encoding
hERG1a were kindly provided by Dr. G. Robertson [20]. The
pCEP4-KCNQ1 and pCEP4-MinK vectors were kindly provided
by Dr. Michael Sanguinetti [40]. To transiently express KCNQ1
and KCNQ1/MinK in HEK-293 cells, the sequences of human
KCNQ1 and Mink were removed from pCEP4 and ligated into
pcDNA 3.1 at the Hind III and BamH I sites for KCNQ1 and at
the Nhe I and EcoR V sites for MinK. Sequence and directionality
were verified by sequencing. The cells were grown in Dulbecco’s
Modified Essential Medium (Invitrogen, CA) at 37uCi n5 %C O 2.
One day before transfection, cells were plated on 35 mm Falcon
culture dishes. Next day, 6 mL of FuGene 6 transfection reagent
(Roche Molecular Biochemicals, IN), 2 mL of solution containing
1.5 mg pcDNA-KCNQ1 or 0.4 mg pcDNA-KCNQ1 plus 4 mg
pcDNA-MinK, and 2 mL of solution containing 0.2 mg pEGFP-
N2 were added to the Eppendorf tube containing 190 mLo f
DMEM, and gently shaken. After 30 min of incubation at room
temperature, contents of the tube were added to the dish with
HEK-293 cells. Recordings were performed 24–48 hours after
transfection from cells displaying moderate green fluorescence.
Chinese hamster ovary (CHO) cells obtained from American
Type Culture Collection (ATCC, P. O. Box 1549, Manassas, VA
20108) were stably transfected [41] with cDNAs encoding the
human cardiac KCND3 channel and KChiP2 (Kv-Channel-
Interacting Protein 2) with resistance to G418 and Zeocin
(Invitrogen, CA) [41]. The cDNA encoding human SCN5A was
stably transfected into HEK-293 cells as described previously [42].
Cells expressing these channels were grown in Ham’s F-12 media
supplemented with 10% foetal bovine serum at 37uCi n5 %C O 2.
Patch-Clamp Recording and data analysis
Whole-cell current recordings and data analysis were performed
using an Axopatch 200B amplifier and pClamp 9.2 software (Axon
Instruments/Molecular Devices, CA). Patch electrodes were
fabricated from thin-walled borosilicate glass (World Precision
Instruments, Sarasota, FL). Electrodes had resistance of 1.0–
3.5 MV. Access resistance was usually less than 10 MV and was
compensated by 80% (no compensation was used for access
resistance less than 3 MV).
For hERG1a and KCNQ1 (KCNQ1/MinK) recordings,
electrodes were filled with the solution: 140.0 mM KCl, 5.4 mM
NaCl, 2.0 mM MgCl2, 1.0 mM CaCl2, 11.0 mM EGTA,
10.0 mM HEPES (pH 7.2). The external solution contained
140.0 mM NaCl, 4.7 mM KCl, 1.2 mM MgCl2, 2.5 mM CaCl2,
10.0 mM HEPES, 11.0 mM glucose, pH 7.4 with NaOH.
KCND3 and SCN5A channel recordings were performed as
described previously [41,42].
All experiments were performed at room temperature (20–
22uC). All values are means 6 S.E.M.; (*): P,0.05, (**): P,0.01
(paired two sample t-test for means or single factor ANOVA as
indicated).
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